We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Scribe Announces Collaboration To Accelerate In Vivo CRISPR-Based Genetic Medicines

The Scribe Therapeutics logo.
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Scribe Therapeutics Inc., a company creating genetic medicines through its CRISPR by Design™ approach to genetic modification, has announced a strategic collaboration with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, granting Prevail exclusive rights to Scribe’s CRISPR X-Editing (XE) technologies for the development of in vivo therapies directed to specified targets known to cause serious neurological and neuromuscular diseases.

“We are thrilled to work with the Prevail team to advance potential treatments for patients facing debilitating genetic diseases,” said Benjamin Oakes, Ph.D., Chief Executive Officer of Scribe.

“With the compelling in vivo proof-of-principle data we have generated in multiple disease areas, Scribe has validated our X-Editing technologies for industry-leading editing activity, specificity and deliverability. Our goal now is to more broadly enable therapies to help people living with these conditions. We are energized by our team’s progress and excited to begin this important work with Prevail.”

Scribe’s platform, enabled by the company’s proprietary CRISPR by Design™ approach, is the first of its kind, applying holistic engineering to transform bacterial immune systems into therapeutically relevant genome editing technologies targeting the specific needs of patients.

The company’s tools for in vivo genome editing directly modify genes within the body, offering several key benefits in safety, efficacy and delivery.